QPS to Assemble Bioanalysis Lab for Analyzing COVID-19 Clinical-Trial Samples

March 30, 2020
Pharmaceutical Technology's In the Lab eNewsletter
Volume 15, Issue 4
Page Number: 12

S is now permitted to import human blood/blood products, other bodily fluids, and tissues that may contain novel coronavirus into its Newark, DE, facility.

QPS, a contract research organization, announced it has assembled an access-restricted bioanalysis lab for analyzing COVID-19 clinical-3trial samples at its facility in Newark, DE.

According to a March 10, 2020 company press release, the US Centers for Disease Control and Prevention’s Department of Health and Human Services granted a permit to QPS enabling the company to import human blood/blood products, other bodily fluids, and tissues that may contain novel coronavirus into its Newark facility.

“In the fight against coronavirus, drug companies need ready access to laboratories equipped to safely manage and analyze samples from ongoing and new clinical trials focused on COVID-19,” said Benjamin Chien, CEO of QPS, in the press release. “We’ve assembled an isolated, restricted access laboratory ready and available to support the life sciences community in determining the safety and efficacy of potential vaccines and treatments for COVID-19 as quickly as possible.”

“Obtaining this permit quickly was a critical step in our business continuity plan and enables QPS to support clients who are urgently working to develop a treatment and/or a vaccine to combat this new coronavirus,” Chien added in the press release. “The scientists in our laboratories have the capability to handle materials contaminated with COVID-19.”

Source: QPS